3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
28
HER2-positive Breast Cancer
4
Neoplasms
3
Multiple Myeloma
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Salivary Gland Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma
1
Interventions
Gemcitabine
15
Cisplatin
13
durvalumab
10
pembrolizumab
9
Oxaliplatin
8
Magnetic Resonance Spectroscopy
8
Specimen Handling
6
Leucovorin
6
Biopsy
6
Fluorouracil
5
Paclitaxel
4
Folfox protocol
4
Taxes
3
Radiation
3
Nivolumab
3
Irinotecan
3
Immunoglobulin G
3
Disulfides
3
tislelizumab
2
pemigatinib
2
olaparib
2
futibatinib
2
fludarabine
2
dehydroftorafur
2
Platinum
2
Liver Transplantation
2
Fluorodeoxyglucose F18
2
Floxuridine
2
Dexamethasone
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
pertuzumab
×
90 days
×
Clear all
No trials found.